5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor
    Meeting Abstract

    De Bono, J. S.; Fizazi, K.; Saad, F.; Taplin, M. E.; Sternberg, C. N.; Miller, K.; Mulders, P.; Chi, K. N.; Armstrong, A. J.; Hirmand, M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Cella, D.; Davis, M. P.; Bushmakin, A. G.; Cappelleri, J. C.; Hahn, E. A.; Korytowsky, B.; Bhattacharyya, H.; Sandin, R.; Beaumont, J. L.; Matczak, E.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC)
    Meeting Abstract

    Balar, A. V.; Iyer, G.; Apolo, A. B.; Regazzi, A. M.; Garcia-Grossman, I. R.; Pendse, D.; Ostrovnaya, I.; Chou, J. F.; Bochner, B.; Dalbagni, G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy
    Meeting Abstract

    Apolo, A. B.; Philips, G.; Ostrovnaya, I.; Rosenberg, J. E.; Milowsky, M. I.; Small, E. J.; Bajorin, D. F.; Halabi, S.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Jia, X.; Heller, G.; Schoder, H.; Humm, J.; Haupt, E. C.; Schneider, C.; Scher, H. I.; Larson, S. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence
    Meeting Abstract

    Bajorin, D. F.; Sharma, P.; Sims, R. B.; Sandler, A.; Lerner, S. P.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study
    Meeting Abstract

    Slovin, S. F.; Hamid, O.; Tejwani, S.; Higano, C. S.; Harzstark, A.; Alumkal, J. J.; Scher, H. I.; Chin, K. M.; Gagnier, P.; McHenry, M. B.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis
    Meeting Abstract

    Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Single nucleotide polymorphisms as markers of bacillus Calmette-Guerin intravesical therapy response in non-muscle invasive bladder cancer
    Meeting Abstract

    Alanee, S.; Hamilton, R. J.; Joseph, V.; Ostrovnaya, I.; Garcia-Grossman, I. R.; Gallagher, D. J.; Pendse, D.; Regazzi, A. M.; Przybylo, J. A.; Gaudet, M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study
    Meeting Abstract

    Scher, H. I.; Fizazi, K.; Saad, F.; Taplin, M. E.; Sternberg, C. N.; Miller, K.; De Wit, R.; Mulders, P.; Hirmand, M.; Selby, B.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save